Where Is the Next EsoBiotec? China’s IIT Ecosystem Is Nurturing the Next $1B CGT Success Story

In March this year, AstraZeneca announced a $1 billion acquisition of Belgian biotech company EsoBiotec.CGTThe circle still maintains a certain level of discussion热度.

1$0 BillionAn important part of the rapid growth process is a clinical study initiated by researchers at Wuhan Union Hospital in China, which took only 8 months.Study (IIT). From signing the contract to production, from project initiation to approval, from patient recruitment to the cure of the first patient, it took only about 8 months in total, with total costs ranging from 600,000 to 800,000 US dollars.

For the lever that uses hundreds of thousands of US dollars to drive billions of US dollars in commercial transformation, many project teams in the industry are already eager to try. But don't be too quick to envy; it's not too late to first clarify the rules and regulations before attempting.

We have observed a notable trend emerging: aside from EsoBiotec, an increasing number of overseas CGT projects are beginning to conduct IITs in China. This is not only to access the vast market but also to take advantage of a "faster, better, and cheaper" clinical validation pathway.

And China is gradually becoming a hotbed for such research. In our exchanges with some industry pioneers, we found that they usually have a few core concerns:

The first reaction of many people is "cost advantage," but this is only part of the story. The deeper value lies inEfficiency and Ecology Synergy。

• "Depth" and "Speed" of Clinical Resources: China's top tertiary hospitals not only have a large patient pool, which can accelerate patient recruitment, but their medical teams also have a strong willingness to explore cutting-edge treatments. This means that a scientifically innovative project can more easily find like-minded clinical partners and advance quickly. For instance, the in vivo cell therapy project ESO-T01 by Belgium's EsoBiotec, conducted as an Investigator-Initiated Trial (IIT) under the leadership of Director Mei Heng at Wuhan Union Hospital, took only about 8 months from initiation to obtaining the first set of human data. Such speed is highly competitive on an international scale.

  
  

• "Seamless Connection" of Mature Industrial ChainsIn China, project teams can efficiently integrate full-chain services from CDMO production, quality testing to clinical operations. The concentration of this ecosystem reduces the损耗of cross-time zone and cross-regulatory communication, as well as significantly cuts costs, allowing researchers to focus more on science and the project itself.

  
  

Amid the ongoing wave of domestic substitution in China, the prices of key materials for production—such as plasmid DNA, lentiviral vectors, and lyophilized filling—have dropped by as much as 70% to 80%. Labor costs are also less than half of those abroad.

The "astronomical drug" label for CGT products has always existed, with high prices and limited patient accessibility being an industry consensus. The ultimate fate of the U.S.-listed pharmaceutical company Bluebird Bio serves as a vivid and specific industry case. Cost data from China's raw material supply chain gives us ample reason to believe,China CDMOCost advantages provide CGT products with pricing power support in the later stages, which can help reduce pressure for subsequent commercialization.

China's regulatory process has its own uniqueness. The key to navigating it in the most efficient and correct way lies in understanding its core aspects and finding the right "guides." Clarifying the entire process can generally be divided into four stages:

• Laying the Foundation (SearchingPI and Deterministic Pathway): Finding a Principal Investigator (PI) who understands your technology and is experienced is the cornerstone of success. Choosing to collaborate directly with a hospital or through a professional project management platform has different focuses, which need to be weighed according to the project strategy.

  
  

• Core Approval (Human Genetic Resources and Ethical Review)：The approval of human genetic resources is a unique and critical step in China, which takes a long time. However, experience shows that introducing professional consulting in the early stage of project design to avoid potential risk points can significantly improve efficiency. Subsequently, the scientific and ethical review by the hospital is the green light to start the research.

  
  

• Clinical Practice (Medication and Implementation): For CGT products, the import of investigational drugs poses a significant challenge. A widely validated and effective strategy is to collaborate with China-based CDMOs certified by international standards, achieving "localization" in the production process. This approach not only bypasses complex import procedures but also benefits long-term development.

  
  

• Output (Data and Intellectual Property): At the beginning of the cooperation, it is a precondition to ensure the rights and interests of all parties and avoid subsequent disputes by clearly defining the ownership of data rights and intellectual property through a clear agreement.

Facing an unfamiliar market and environment, a partner who is familiar with local rules and has extensive resources becomes particularly important. Against this backdrop, the China Cell and Gene Therapy Consortium (CSGCT) has gradually come into the view of many international CGT project innovators. The value of CSGCT lies not only in providing a list of institutions but also in the integration and coordination capabilities of its platform.

• Precise"Navigation" Function:CSGCT can help connect the most suitable clinical centers and PIs based on the specific scientific field of the project, saving you from blindly searching through massive amounts of information.

  
  

• Professional"The Role of 'Translation' and 'Bridge':"The CSGCT Expert Committee is familiar with the review logic and focus points of regulatory agencies. They can provide forward-looking advice during the project planning phase and assist in efficient communication with all parties, transforming your scientific language into a systematic engineering effort that complies with local regulations.

  
  

• Ecological"Connector" Function:From clinical centers, CDMOs to legal consultants, CSGCT can connect a reliable service network to ensure professional support at every critical node of the project.

  
  

• Experienced "Mine Sweeper" Function:BelgiumThe CGT project of EsoBiotec completed the IIT at Wuhan Union Hospital, which was operated by the core member unit of CSGCT. Many member units of CSGCT have complete and mature IIT operation systems and successful cases, which can help applicants eliminate "pitfalls" in the project process.

For overseas CGT projects seeking rapid and efficient clinical validation, the value of the Chinese market is shifting from a "cost option" to a "strategic option." Its unique clinical resources, mature industrial ecosystem, and increasingly clear regulatory pathways create strong appeal. The key to success lies in choosing a partner who deeply understands your science and is well-versed in local practice rules, to jointly navigate this opportunity-filled path. If you are evaluating IIT as the next step for your CGT project, it may be worth taking the time to explore the possibilities offered by platforms in China.

Peking University Cancer Hospital

Peking University Third Hospital

Gaobo Medical Group

Ruijin Hospital

West China Hospital of Sichuan University

American-Chinese Aire Cancer Hospital